EGFR and non-small cell lung carcinoma: However, Heon et al. [36] retrospectively explored the risk of CNS progression in patients with IIIB/IV NSCLC initially treated with EGFR-TKIs, and drew an opposite conclusion that a higher risk of CNS progression was observed in patients bearing exon 19 deletion mutations.